CN1169826C - 一种新的化合物异甘草酸镁及其生产方法和用途 - Google Patents
一种新的化合物异甘草酸镁及其生产方法和用途 Download PDFInfo
- Publication number
- CN1169826C CN1169826C CNB021116938A CN02111693A CN1169826C CN 1169826 C CN1169826 C CN 1169826C CN B021116938 A CNB021116938 A CN B021116938A CN 02111693 A CN02111693 A CN 02111693A CN 1169826 C CN1169826 C CN 1169826C
- Authority
- CN
- China
- Prior art keywords
- isoglycyrrhetate
- magnesium
- acid
- magnesium isoglycyrrhetate
- isoglycyrrhiza
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000011777 magnesium Substances 0.000 title claims abstract description 42
- 229910052749 magnesium Inorganic materials 0.000 title claims abstract description 40
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 title claims abstract description 38
- 238000000034 method Methods 0.000 title claims abstract description 9
- 230000008569 process Effects 0.000 title abstract description 5
- 239000002253 acid Substances 0.000 claims abstract description 39
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims abstract description 26
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims abstract description 12
- 150000004702 methyl esters Chemical class 0.000 claims abstract description 12
- 238000004519 manufacturing process Methods 0.000 claims abstract description 11
- 239000003513 alkali Substances 0.000 claims abstract description 8
- 150000001875 compounds Chemical class 0.000 claims abstract description 7
- 239000012535 impurity Substances 0.000 claims abstract description 7
- 208000019423 liver disease Diseases 0.000 claims abstract description 7
- 238000006317 isomerization reaction Methods 0.000 claims abstract description 6
- 238000007254 oxidation reaction Methods 0.000 claims abstract description 6
- -1 pyranose aldehyde Chemical class 0.000 claims abstract description 5
- 239000000126 substance Substances 0.000 claims abstract description 5
- 229930182470 glycoside Natural products 0.000 claims abstract description 4
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims description 26
- 238000000605 extraction Methods 0.000 claims description 4
- 230000007062 hydrolysis Effects 0.000 claims description 4
- 238000006460 hydrolysis reaction Methods 0.000 claims description 4
- OGWLTJRQYVEDMR-UHFFFAOYSA-F tetramagnesium;tetracarbonate Chemical compound [Mg+2].[Mg+2].[Mg+2].[Mg+2].[O-]C([O-])=O.[O-]C([O-])=O.[O-]C([O-])=O.[O-]C([O-])=O OGWLTJRQYVEDMR-UHFFFAOYSA-F 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 159000000003 magnesium salts Chemical class 0.000 claims description 3
- 150000002966 pentacyclic triterpenoids Chemical class 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 2
- 150000002680 magnesium Chemical class 0.000 claims description 2
- 239000012452 mother liquor Substances 0.000 claims description 2
- 238000006386 neutralization reaction Methods 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 239000000047 product Substances 0.000 abstract description 9
- 238000006243 chemical reaction Methods 0.000 abstract description 3
- 241000282414 Homo sapiens Species 0.000 abstract description 2
- 238000005815 base catalysis Methods 0.000 abstract 1
- 239000007795 chemical reaction product Substances 0.000 abstract 1
- 239000012024 dehydrating agents Substances 0.000 abstract 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 abstract 1
- 206010067125 Liver injury Diseases 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 102000003929 Transaminases Human genes 0.000 description 7
- 108090000340 Transaminases Proteins 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 6
- 231100000012 chronic liver injury Toxicity 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000002504 physiological saline solution Substances 0.000 description 5
- 231100000572 poisoning Toxicity 0.000 description 5
- 230000000607 poisoning effect Effects 0.000 description 5
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 230000009466 transformation Effects 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- 102000009027 Albumins Human genes 0.000 description 4
- 108010088751 Albumins Proteins 0.000 description 4
- 101710092506 Aspartate aminotransferase Proteins 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 101710101107 Probable aspartate aminotransferase Proteins 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 239000002574 poison Substances 0.000 description 4
- 231100000614 poison Toxicity 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 231100000234 hepatic damage Toxicity 0.000 description 3
- 206010019692 hepatic necrosis Diseases 0.000 description 3
- 230000007866 hepatic necrosis Effects 0.000 description 3
- ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 description 3
- 210000005229 liver cell Anatomy 0.000 description 3
- 230000008818 liver damage Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- ILRKKHJEINIICQ-OOFFSTKBSA-N Monoammonium glycyrrhizinate Chemical compound N.O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O ILRKKHJEINIICQ-OOFFSTKBSA-N 0.000 description 2
- SQVRNKJHWKZAKO-PFQGKNLYSA-N N-acetyl-beta-neuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-PFQGKNLYSA-N 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 231100000439 acute liver injury Toxicity 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 238000006555 catalytic reaction Methods 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 238000000921 elemental analysis Methods 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 230000004761 fibrosis Effects 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 108010074605 gamma-Globulins Proteins 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 2
- 239000001117 sulphuric acid Substances 0.000 description 2
- 235000011149 sulphuric acid Nutrition 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 206010019668 Hepatic fibrosis Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- GQPLMRYTRLFLPF-UHFFFAOYSA-N Nitrous Oxide Chemical compound [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000334 hepatotoxic Toxicity 0.000 description 1
- 230000003082 hepatotoxic effect Effects 0.000 description 1
- 230000005745 host immune response Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000452 restraining effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Abstract
Description
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB021116938A CN1169826C (zh) | 2002-05-16 | 2002-05-16 | 一种新的化合物异甘草酸镁及其生产方法和用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB021116938A CN1169826C (zh) | 2002-05-16 | 2002-05-16 | 一种新的化合物异甘草酸镁及其生产方法和用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1381463A CN1381463A (zh) | 2002-11-27 |
CN1169826C true CN1169826C (zh) | 2004-10-06 |
Family
ID=4741692
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB021116938A Expired - Lifetime CN1169826C (zh) | 2002-05-16 | 2002-05-16 | 一种新的化合物异甘草酸镁及其生产方法和用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1169826C (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019196920A1 (zh) * | 2018-04-13 | 2019-10-17 | 正大天晴药业集团股份有限公司 | 甘草酸衍生物的结晶、其结晶组合物、药物组合物及用途 |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100381124C (zh) * | 2004-09-09 | 2008-04-16 | 江苏正大天晴药业股份有限公司 | 异甘草酸镁凝胶剂及其制备方法和应用 |
CN101062047B (zh) * | 2006-04-29 | 2010-06-09 | 江苏正大天晴药业股份有限公司 | 一种含有异甘草酸和苦参素的组合物及其用途 |
CN102584928B (zh) * | 2011-12-02 | 2014-04-02 | 杭州市第六人民医院 | 一种反式甘草酸的制备方法 |
CN103242392B (zh) * | 2012-02-13 | 2016-04-13 | 南京华狮化工有限公司 | 一种甘草酸复盐及其制备与应用 |
CN104861031A (zh) * | 2015-03-16 | 2015-08-26 | 李玉山 | 一种异甘草酸镁的制备方法 |
CN107970248A (zh) * | 2016-10-21 | 2018-05-01 | 正大天晴药业集团股份有限公司 | 异甘草酸在制备治疗高血压药物中的用途 |
CN109486895A (zh) * | 2018-12-04 | 2019-03-19 | 南京工业大学 | 一种催化拆分制备异甘草酸的方法 |
CN109486896A (zh) * | 2018-12-04 | 2019-03-19 | 南京工业大学 | 一种催化拆分制备异甘草酸的方法 |
-
2002
- 2002-05-16 CN CNB021116938A patent/CN1169826C/zh not_active Expired - Lifetime
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019196920A1 (zh) * | 2018-04-13 | 2019-10-17 | 正大天晴药业集团股份有限公司 | 甘草酸衍生物的结晶、其结晶组合物、药物组合物及用途 |
CN111918869A (zh) * | 2018-04-13 | 2020-11-10 | 正大天晴药业集团股份有限公司 | 甘草酸衍生物的结晶、其结晶组合物、药物组合物及用途 |
US11292809B2 (en) | 2018-04-13 | 2022-04-05 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Crystals of glycyrrhizic acid derivatives, crystalline compositions, pharmaceutical compositions and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
CN1381463A (zh) | 2002-11-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1169826C (zh) | 一种新的化合物异甘草酸镁及其生产方法和用途 | |
CN1164588C (zh) | 黄连素及其盐类的制备方法 | |
CN1296379C (zh) | 丙二酰基人参皂苷的制备工艺及其治疗糖尿病的药物用途 | |
CN1861580A (zh) | 从植物中提取石杉碱甲的工艺 | |
CN1884260A (zh) | 一种化合物、其合成方法及其在制备驱除重金属和清除自由基药物中的应用 | |
CN1256090C (zh) | 积雪草酸及其衍生物在制备抗抑郁药物中的应用 | |
CN1772745A (zh) | 一种霉酚酸莫啡酯的制备方法 | |
CN1813860A (zh) | 一种脑心清分散片及其制备工艺 | |
CN1219757C (zh) | 磺化去氢松香酸盐及其制备方法和其用途 | |
CN1381462A (zh) | 新的化合物异甘草酸盐及其生产方法 | |
CN1775791A (zh) | 一种制备2-脱氧-d-葡萄糖的新方法 | |
CN1099293C (zh) | 一种降血脂制剂及其工艺和应用 | |
CN1169825C (zh) | 从皂角中提取皂角三萜酸的方法及皂角三萜酸的医药用途和中药制剂 | |
CN1250547C (zh) | 从苦豆籽中提取苦参碱、槐定碱的工艺 | |
CN1706836A (zh) | 一种从海藻中分离岩藻黄素的方法 | |
CN1543876A (zh) | 一种新型红曲口服液及其生产方法 | |
CN1882526A (zh) | 制备伏格列波糖的方法 | |
CN1274656C (zh) | 光学纯α—卤代酸的制备工艺 | |
CN1327446A (zh) | 新药物 | |
CN1157395C (zh) | 一种制备总缬草素浸膏的方法 | |
CN1709904A (zh) | 提取薯蓣皂素的汽化酸酸解法 | |
CN1704429A (zh) | 异甘草酸有机胺盐及其制备方法和用途 | |
CN1736461A (zh) | 治疗ⅱ型糖尿病和胰岛素增敏的组合植物药及提取物及提取方法 | |
CN1554333A (zh) | 右旋西布曲明及其相应的盐在制备减肥药物中的用途 | |
CN1243772C (zh) | 蝙蝠葛碱提多糖及其提取方法和以该化合物为活性成分的药物用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: JIANGSU ZHENGDA TIANQING PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: WU XIMING Free format text: FORMER OWNER: WANG PEI Effective date: 20050304 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20050304 Address after: 222006 No. 8 Julong North Road, Sinpo District, Jiangsu, Lianyungang Patentee after: Jiangsu Chiatai Tianqing Pharmaceutical Co., Ltd. Address before: 201, room 2, unit 386, Feng Feng Road, 310006, Zhejiang, Hangzhou Co-patentee before: Wang Pei Patentee before: Wu Ximing |
|
C56 | Change in the name or address of the patentee |
Owner name: CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. Free format text: FORMER NAME: JIANGSU ZHENGDA TIANQING PHARMACEUTICAL CO., LTD. |
|
CP01 | Change in the name or title of a patent holder |
Address after: 222006 Sinpo City, Lianyungang Province, North Road, No. 8, No. Patentee after: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Address before: 222006 Sinpo City, Lianyungang Province, North Road, No. 8, No. Patentee before: Jiangsu Chiatai Tianqing Pharmaceutical Co., Ltd. |
|
CX01 | Expiry of patent term | ||
CX01 | Expiry of patent term |
Granted publication date: 20041006 |